We are live on
!
Find out more
ESPR
Esperion Therapeutics
ESPR
ESPR
Delisted
ESPR was delisted on the 10th of July, 2026.
101 hedge funds and large institutions have $190M invested in Esperion Therapeutics in 2016 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 28 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
29% more capital invested
Capital invested by funds: $148M → $190M (+$42.4M)
7% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 28
1% less funds holding
Funds holding: 102 → 101 (-1)
1% less call options, than puts
Call options by funds: $2.74M | Put options by funds: $2.77M
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
Holders
101
Holders Change
-1
Holders Change %
-0.98%
% of All Funds
2.69%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
15
Increased
30
Reduced
28
Closed
16
Calls
$2.74M
Puts
$2.77M
Net Calls
-$30K
Net Calls Change
+$199K
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$3.61M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$3.4M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$1.91M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.05M |
| 5 |
IHM
Iguana Healthcare Management
New York
|
+$907K |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.43M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.76M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
-$2.74M |
| 4 |
FMA
FNY Managed Accounts
New York
|
-$2.27M |
| 5 |
SAM
Senzar Asset Management
New York
|
-$2.17M |
